Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834793 · ClinicalTrials.gov registry record · Phase 3
Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
A Phase 3 study, sponsored by Eisai.
- Terminated
- Registry status
- Phase 3
- Development phase
- 101
- Enrollment target
NCT02834793 is a Phase 3 study that was terminated before completion, run by Eisai. The registered enrollment target is 101 participants.
The verdict
NCT02834793, a Phase 3 study, was terminated before completion, sponsored by Eisai.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 101 participants
- Enrollment target
Study Summary
This study is being conducted to demonstrate that perampanel given as adjunctive anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS).
Interventions
- DRUG Placebo
- DRUG Perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-12-13 |
| Est. Completion | 2021-07-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02834793
The ClinicalTrials.gov registry entry for NCT02834793 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02834793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02834793 about?
NCT02834793 is a clinical study titled "Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome". This study is being conducted to demonstrate that perampanel given as adjunctive anti-epileptic treatment is superior to placebo in reducing the number of drop seizures in participants with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS).
What is the current status of trial NCT02834793?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 101 participants. The study started on 2016-12-13. Estimated completion is 2021-07-19.
What interventions are being tested in trial NCT02834793?
The interventions under investigation include: Placebo (DRUG), Perampanel (DRUG).
Who is sponsoring clinical trial NCT02834793?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.